To develop a novel 3D-QSAR approach for study of the epidermal growth factor receptor tyrosine kinase (EGFR TK) and its inhibitors. Most EGFR TKIs are quinazoline-derivatives with diverse functional ...
Activating mutations on the EGFR protein, including exon 20 insertion mutations, have a role in NSCLC, but the associated structural changes resulting from the V769insASV and D770insNPG EGFR exon 20 ...
HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provides an ...
Eradication of p53-mutated head and neck squamous cell carcinoma (HNSCC) xenografts using nonviral p53 gene therapy and photochemical internalisation (PCI) This is an ASCO Meeting Abstract from the ...
Researchers have found that two drugs bind to receptor sites on some tumors in different places at the same time, suggesting the possibility of a new combination therapy for certain types of cancer.
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the “Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline ...
The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results No significant financial relationships to ...
† US FDA-approved drugs; for more information see [15]. EGFR: EGF receptor; FGFR: FGF receptor; NSCLC: Non-small-cell lung cancer; VEGFR: VEGF receptor. Table 2. Different tyrosine kinase inhibitors ...
BOSTON - ALX Oncology Holdings Inc. (NASDAQ:ALXO), a clinical-stage biotech company with a market capitalization of $94 million that according to InvestingPro analysis appears slightly undervalued, ...
PHILADELPHIA - Researchers from the University of Pennsylvania School of Medicine and colleagues at Merck Serono Research in Germany have found that two drugs bind to receptor sites on some tumors in ...
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback